Neurogene Analyst Price Targets - Benzinga

Neurogene Inc

NGNENASDAQ

Trade with Public

Trade with Public

$25.45

-1.02-3.85%

Dern. MÀJ: Oct 6, 4:00 PM

$25.45

-1.02-3.85%

Aperçu Actualités Prévisions de résultats ÉvénementsObjectifs de coursDonnées financières Sentiment Actionnariat Comparer Options Rapport sur les stocks

Neurogene Analyst Price Targets - Benzinga

Neurogene Analyst Price Targets

Wall Street analyst price targets and consensus rating for Neurogene (NGNE).

Price Target Range — 10 Quarters

Analyst Consensus — 10 Analysts

9Buy

1Hold

Consensus RatingBuy# Analysts10Avg. Consensus PT$60Upside to Avg. PT+134.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 12, 2026	Canaccord Genuity	Whitney Ijem	PT Cut	Buy	$180→$166
Aug 12, 2026	Guggenheim	Debjit Chattopadhyay	PT Raise	Buy	$69→$81
Aug 12, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Buy	$70→$65
Jun 9, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$70
Apr 6, 2026	Canaccord Genuity	Whitney Ijem	PT Cut	Buy	$200→$180
Feb 27, 2026	Canaccord Genuity	Whitney Ijem	Initiate	Buy	$200
Jan 26, 2026	LifeSci Capital	Patrick Dolezal	Initiate	Outperform	$50
Jan 13, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$70
Nov 13, 2025	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Buy	$65→$70
Oct 31, 2025	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Buy	$45→$65
Oct 9, 2025	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$45
Jun 17, 2025	Craig-Hallum	Albert Lowe	Initiate	Buy	$50
Jun 12, 2025	BMO Capital	Evan David Seigerman	PT Raise	Outperform	$22→$26
May 20, 2025	BMO Capital	Evan David Seigerman	PT Raise	Outperform	$16→$22
May 16, 2025	Baird	Joel Beatty	Downgrade	Outperform→Neutral	$38→$24
May 13, 2025	HC Wainwright & Co.	Mitchell Kapoor	PT Cut	Buy	$50→$45
Apr 14, 2025	BMO Capital	Keith Tapper	PT Cut	Outperform	$45→$16
Mar 25, 2025	Baird	Joel Beatty	PT Cut	Outperform	$46→$36
Mar 25, 2025	HC Wainwright & Co.	Mitchell Kapoor	PT Cut	Buy	$55→$50
Nov 25, 2024	HC Wainwright & Co.	Mitchell Kapoor	Maintained	Buy	$55

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Canaccord Genuity Maintains Buy on Neurogene, Lowers Price Target to $166

Canaccord Genuity analyst Whitney Ijem maintains Neurogene (NASDAQ:NGNE) with a Buy and lowers the price target from $180 to $166.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Neurogene, Raises Price Target to $81

Guggenheim analyst Debjit Chattopadhyay maintains Neurogene (NASDAQ:NGNE) with a Buy and raises the price target from $69 to $81.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Neurogene, Lowers Price Target to $65

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Neurogene (NASDAQ:NGNE) with a Buy and lowers the price target from $70 to $65.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Neurogene, Maintains $70 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Neurogene (NASDAQ:NGNE) with a Buy and maintains $70 price target.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Neurogene, Lowers Price Target to $180

Canaccord Genuity analyst Whitney Ijem maintains Neurogene (NASDAQ:NGNE) with a Buy and lowers the price target from $200 to $180.

Benzinga Newsdesk

PRO
Canaccord Genuity Initiates Coverage On Neurogene with Buy Rating, Announces Price Target of $200

Canaccord Genuity analyst Whitney Ijem initiates coverage on Neurogene (NASDAQ:NGNE) with a Buy rating and announces Price Target of $200.

Benzinga Newsdesk